Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer
The aims of the study are to reduce acute radiation induced side effects, i.e. pneumonitis and esophagitis grade II or higher by the use of proton therapy compared to photon radiotherapy of equal total dose. Secondary endpoints include evaluation of quality of life, loco-regional control, survival and late radiation induced side effects.
• NSCLC (confirmed by cytology or histology) staged UICC IIIA or IIIB or UICC II if the patient declines surgery
• no distant metastases (M1)
• patient' age between 18 and 70 years
• Patient medically suited for primary radiochemotherapy with curative intent
• signed declaration of informed consent
• adequate compliance for treatment and clinical follow up
• adequate contraception during and after therapy if indicated